Class II
Ongoing
fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.
Why: cGMP deviations.
- Company
- Wells Pharma of Houston LLC
Houston, TX, United States - Reported
- May 6, 2026
- Recall started
- Apr 1, 2026
- Where sold
- U.S. Nationwide.
- Amount
- 50 syringes
- Full product description
- fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.
- Lots / codes affected
- Lot 020226202150202, Exp Date 05/05/2026.
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.